Key result
Later endovascular therapy eras for CLTI show no difference in mortality or amputation despite fewer reinterventions.
Why the study?
How have the characteristics and outcomes of patients with chronic limb-threatening ischemia undergoing endovascular therapy changed over time?
Cohort (n=2,085)
Yes
How have the characteristics and outcomes of patients with chronic limb-threatening ischemia undergoing endovascular therapy changed over time?
Answers are grounded in this paper and cite their sources.
Over a 13-year period, patients with CLTI undergoing endovascular therapy presented with higher anatomical severity but experienced significantly lower 1-year reintervention rates, with no change in mortality or major amputation.
BACKGROUND: Due to an aging population and the growing prevalence of diabetes, patients with chronic limb-threatening ischemia (CLTI) represent a growing burden on health care and social services. OBJECTIVES: This study aimed to investigate the trends in characteristics and treatment of patients with CLTI. METHODS: This multicenter retrospective study included 2,085 patients with CLTI who underwent endovascular therapy between April 2010 and March 2023. Clinical characteristics and outcomes were compared among 4 groups based on treatment period quartiles (Q1-Q4). The clinical characteristics of the patients, limbs, and anatomical severity were assessed according to the global vascular guidelines. The outcome measures were mortality or major amputation rate, and reintervention rate. RESULTS: The median follow-up period was 14.9 months (IQR: 3.9-36.5 months). In the later periods, patient risk was higher, wound severity was lower, and anatomical severity was higher in inframalleolar lesions (each P < 0.05). The mortality or major amputation rate at 1 year did not significantly differ across Q1-Q4 (24.2% [95% CI: 20.5%-28.5%], 22.7% [95% CI: 19.0%-27.0%], 25.6% [95% CI: 21.8%-30.0%], and 28.9% [95% CI: 24.7%-33.5%] in Q1-Q4, respectively; P for trend = 0.18). The reintervention rate at 1 year was significantly lower in the later periods (43.2% [95% CI: 38.5%-48.3%], 45.2% [95% CI: 40.4%-50.4%], 37.8% [95% CI: 33.2%-42.8%], and 32.5% [95% CI: 27.9%-37.6%] in Q1-Q4, respectively; P for trend = 0.002). CONCLUSIONS: The characteristics of patients with CLTI were significantly different across the treatment period. The mortality or major amputation rates did not significantly different, whereas the reintervention rate was significantly lower in the later periods.
No takes yet. Share an insight, caveat, or question.
Hata et al. (2025) conducted a cohort in Chronic limb-threatening ischemia (CLTI) (n=2,085). Later treatment periods (Q4) vs. Earlier treatment periods (Q1) was evaluated on Mortality or major amputation rate at 1 year (p=0.18). Later treatment periods for endovascular therapy in CLTI showed similar 1-year mortality or major amputation rates but lower reintervention rates.
Synapse has enriched 10 related papers. Consider them for comparative context: